The mutation in SMARCA4 affects chromatin accessibility and reduces expression of the transcription factor, ATF3, which negatively regulates transcription of the anti-apoptotic gene BCL-xL, leading to the observed resistance of MCL cells to therapy [66]. This evidence concerns the gene SMARCA4 and mantle cell lymphoma.